MYCN and neuroblastoma: ASCL1 is downregulated during neuroblastoma cell differentiation along with upregulation of several genes including IGF2 [25]; moreover, the negative correlation of ASCL1 expression with neuronal differentiation is independent from MYCN gene expression, suggesting that targeting ASCL1 might increase the efficacy of retinoic acid-based differentiating therapies in neuroblastoma [26].